Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Alza Corporation, DE, USA |
---|---|
Information provided by: | Alza Corporation, DE, USA |
ClinicalTrials.gov Identifier: | NCT00399295 |
The purpose of this study was to compare the pharmacokinetic (the way a drug enters and leaves the blood and tissues over time) profile of Dilaudid OROS 16mg (Dilaudid Slow Release; hydromorphone HCL) administered under fasting conditions, following a high-fat breakfast meal. The study also examined the effect of naltrexone blockade on the pharmacokinetic profile of Dilaudid SR.
Condition | Intervention | Phase |
---|---|---|
Analgesia |
Drug: Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg. |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Bio-availability Study |
Official Title: | An Open-Label Evaluation of the Independent Effect of Coadministration of a High Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCL) 16 mg |
Estimated Enrollment: | 30 |
Study Completion Date: | June 1997 |
This was a randomized (patients are assigned different treatments based on chance), open-label, three-way crossover study, performed in normal, healthy adults. Each patient received orally administered treatments (a different treatment during each dosing phase): Treatment A: single dose of Dilaudid SR 16 mg administered under fasting conditions without the naltrexone block;Treatment B: single dose of Dilaudid SR 16 mg administered under fed conditions without the naltrexone block, Treatment C: single dose of Dilaudid SR 16 mg administered under fasting conditions with naltrexone HCL 50mg block (3 oral doses of 50mg each administered 12 hours prior to , at the time of, and 12 hours after Dilaudid SR 16mg administration). There was a 7-day washout period between dosing phases. Venous blood sampling times were 0 (prior to dosing),2,4,6,8,10,12,16,20,24,30,36,42,and 48 hours after each Dilaudid SR administration. LC/MS/MS (Liquid Chromatography/Mass Spectroscopy/Mass Spectroscopy)techniques were employed for the analysis of plasma for hydromorphone concentration.
Each patient randomly received orally-administered treatments of single dose of Dilaudid SR 16mg; under fasting conditions without the naltrexone block; under fed conditions without naltrexone block; under fasting conditions with naltrexone 50mg block (3 oral doses of 50mg naltrexone HCL each administered 12 hours prior to, at the time of, and 12 hours after hydromorphone administration); 7-day washout period between dosing phases.
Ages Eligible for Study: | 19 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CR011608 |
Study First Received: | November 10, 2006 |
Last Updated: | April 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00399295 History of Changes |
Health Authority: | United States: Institutional Review Board |
Analgesia |
Hydromorphone Narcotic Antagonists Naltrexone Central Nervous System Depressants |
Narcotics Peripheral Nervous System Agents Analgesics Analgesics, Opioid |
Hydromorphone Narcotic Antagonists Physiological Effects of Drugs Central Nervous System Depressants Narcotics Pharmacologic Actions Sensory System Agents |
Therapeutic Uses Naltrexone Analgesics Peripheral Nervous System Agents Central Nervous System Agents Analgesics, Opioid |